Differential susceptibility of pine weevil, Hylobius abietis (Coleoptera: Curculionidae), larvae and pupae to entomopathogenic nematodes and death of adults infected as pupae

The large pine weevil Hylobius abietis is a serious pest of reforestation in northern Europe. Development takes place in the stumps of felled conifer trees and emerging adults feed on and kill newly planted trees. Application of entomopathogenic nematodes around tree stumps has been shown to reduce the emergence of adult weevils. In order to target application at the most susceptible stage, the susceptibility of larvae and pupae to Heterorhabditis downesi and Steinernema carpocapsae was compared in a close-contact assay on filter paper. An average of 95.8 % of larvae were killed by H. downesi and 82.1 % by S. carpocapsae while only 16.3 and 15.0 % of pupae were killed by these two species, respectively. However, many of the H. abietis that were exposed as pupae died after metamorphosis to callow adult, with mortality of pupae and callow adults combined reaching 62.5 % for H. downesi and 69.9 % for S. carpocapsae. For both nematode species significantly more insects died as larvae than as either pupae or pupae/callow adults. When pupae were exposed to infective juveniles (IJs) for 2 days and were then washed while still pupae to remove surface IJs, adults were later found to be infected indicating that IJs can infect pupae, survive metamorphosis and subsequently kill adults

Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom?

The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for the treatment of disease resistance or intolerance to the first-choice or second-choice drug. The availability of different drugs is a major achievement, but means that choices must be made-which can be difficult and questionable at times. The most important end point considered in decision-making regarding treatment for any cancer is overall survival, but additional factors (such as age, prognostic category, safety, or the possibility of achieving treatment-free remission) should be considered when selecting an agent for frontline treatment. Regardless of the TKI selected for first-line treatment, guidelines that define the importance of reaching specific response indicators and procedures for vigilant follow-up monitoring are established to ensure timely implementation of second-line TKIs. Herein, we discuss the benefits and risks of the different TKIs available for the treatment of patients with CML, and how to decide when to employ these agents at different treatment settings